|
1
|
Ostrom QT, Bauchet L, Davis FG, Deltour I,
Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh
KM, et al: The epidemiology of glioma in adults: A 'state of the
science' review. Neuro-oncol. 16:896–913. 2014. View Article : Google Scholar
|
|
2
|
Rao JS: Molecular mechanisms of glioma
invasiveness: The role of proteases. Nat Rev Cancer. 3:489–501.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gupta K and Salunke P: Molecular markers
of glioma: An update on recent progress and perspectives. J Cancer
Res Clin Oncol. 138:1971–1981. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Larjavaara S, Mäntylä R, Salminen T,
Haapasalo H, Raitanen J, Jääskeläinen J and Auvinen A: Incidence of
gliomas by anatomic location. Neuro-oncol. 9:319–325. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martin S, Janouskova H and Dontenwill M:
Integrins and p53 pathways in glioblastoma resistance to
temozolomide. Front Oncol. 2:1572012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pegg AE: Repair of O(6)-alkylguanine by
alkyltransferases. Mutat Res. 462:83–100. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kleer CG: Dual roles of CCN proteins in
breast cancer progression. J Cell Commun Signal. 10:217–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Holbourn KP, Acharya KR and Perbal B: The
CCN family of proteins: Structure-function relationships. Trends
Biochem Sci. 33:461–473. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gurbuz I and Chiquet-Ehrismann R:
CCN4/WISP1 (WNT1 inducible signaling pathway protein 1): A focus on
its role in cancer. Int J Biochem Cell Biol. 62:142–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu J, Long Z, Cai H, Du C, Liu X, Yu S and
Wang Y: High expression of WISP1 in colon cancer is associated with
apoptosis, invasion and poor prognosis. Oncotarget. 7:49834–49847.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chuang JY, Chen PC, Tsao CW, Chang AC,
Lein MY, Lin CC, Wang SW, Lin CW and Tang CH: WISP-1 a novel
angiogenic regulator of the CCN family promotes oral squamous cell
carcinoma angiogenesis through VEGF-A expression. Oncotarget.
6:4239–4252. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang H, Luo H, Hu Z, Peng J, Jiang Z,
Song T, Wu B, Yue J, Zhou R, Xie R, et al: Targeting WISP1 to
sensitize esophageal squamous cell carcinoma to irradiation.
Oncotarget. 6:6218–6234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang H, Luo H, Jiang Z, Yue J, Hou Q, Xie
R and Wu S: Fractionated irradiation-induced EMT-like phenotype
conferred radioresistance in esophageal squamous cell carcinoma. J
Radiat Res (Tokyo). 57:370–380. 2016. View Article : Google Scholar
|
|
14
|
Yu W, Song T, Shi L, Wang X, Jiang Z,
Zhang H and Wu S: Targeted inhibition of WISP1 enhanced
radiosensitivity in glioma cells. Zhonghua Yi Xue Za Zhi.
94:1507–1511. 2014.In Chinese. PubMed/NCBI
|
|
15
|
Minchenko OH, Kharkova AP, Minchenko DO
and Karbovskyi LL: Effect of hypoxia on the expression of genes
that encode some IGFBP and CCN proteins in U87 glioma cells depends
on IRE1 signaling. Ukr Biochem J. 87:52–63. 2015. View Article : Google Scholar
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 (−Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
17
|
Jun JI and Lau LF: Taking aim at the
extracellular matrix: CCN proteins as emerging therapeutic targets.
Nat Rev Drug Discov. 10:945–963. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie D, Nakachi K, Wang H, Elashoff R and
Koeffler HP: Elevated levels of connective tissue growth factor,
WISP-1, and CYR61 in primary breast cancers associated with more
advanced features. Cancer Res. 61:8917–8923. 2001.PubMed/NCBI
|
|
19
|
Tian C, Zhou ZG, Meng WJ, Sun XF, Yu YY,
Li L, Luo HZ, Yang L, Zhou B and Gu J: Overexpression of connective
tissue growth factor WISP-1 in Chinese primary rectal cancer
patients. World J Gastroenterol. 13:3878–3882. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagai Y, Watanabe M, Ishikawa S, Karashima
R, Kurashige J, Iwagami S, Iwatsuki M, Baba Y, Imamura Y, Hayashi
N, et al: Clinical significance of Wnt-induced secreted protein-1
(WISP-1/CCN4) in esophageal squamous cell carcinoma. Anticancer
Res. 31:991–997. 2011.PubMed/NCBI
|
|
21
|
Shao H, Cai L, Grichnik JM, Livingstone
AS, Velazquez OC and Liu ZJ: Activation of Notch1 signaling in
stromal fibroblasts inhibits melanoma growth by upregulating
WISP-1. Oncogene. 30:4316–4326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ono M, Inkson CA, Sonn R, Kilts TM, de
Castro LF, Maeda A, Fisher LW, Robey PG, Berendsen AD, Li L, et al:
WISP1/CCN4: A potential target for inhibiting prostate cancer
growth and spread to bone. PLoS One. 8:e717092013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
De Salvo M, Maresca G, D'agnano I,
Marchese R, Stigliano A, Gagliassi R, Brunetti E, Raza GH, De Paula
U and Bucci B: Temozolomide induced c-Myc-mediated apoptosis via
Akt signalling in MGMT expressing glioblastoma cells. Int J Radiat
Biol. 87:518–533. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nagasawa DT, Chow F, Yew A, Kim W, Cremer
N and Yang I: Temozolomide and other potential agents for the
treatment of glioblastoma multiforme. Neurosurg Clin N Am.
23:307–322. ix2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stavrovskaya AA, Shushanov SS and
Rybalkina EY: Problems of glioblastoma multiforme drug resistance.
Biochemistry (Mosc). 81:91–100. 2016. View Article : Google Scholar
|
|
26
|
Luo H, Chen Z, Wang S, Zhang R, Qiu W,
Zhao L, Peng C, Xu R, Chen W, Wang HW, et al: c-Myc-miR-29c-REV3L
signalling pathway drives the acquisition of temozolomide
resistance in glioblastoma. Brain. 138:3654–3672. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nie E, Jin X, Wu W, Yu T, Zhou X, Zhi T,
Shi Z, Zhang J, Liu N and You Y: BACH1 promotes temozolomide
resistance in glioblastoma through antagonizing the function of
p53. Sci Rep. 6:397432016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li DM and Feng YM: Signaling mechanism of
cell adhesion molecules in breast cancer metastasis: Potential
therapeutic targets. Breast Cancer Res Treat. 128:7–21. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huan J, Wang L, Xing L, Qin X, Feng L, Pan
X and Zhu L: Insights into significant pathways and gene
interaction networks underlying breast cancer cell line MCF-7
treated with 17β-estradiol (E2). Gene. 533:346–355. 2014.
View Article : Google Scholar
|
|
30
|
Burotto M, Chiou VL, Lee JM and Kohn EC:
The MAPK pathway across different malignancies: A new perspective.
Cancer. 120:3446–3456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Choe G, Park JK, Jouben-Steele L, Kremen
TJ, Liau LM, Vinters HV, Cloughesy TF and Mischel PS: Active matrix
metalloproteinase 9 expression is associated with primary
glioblastoma subtype. Clin Cancer Res. 8:2894–2901. 2002.PubMed/NCBI
|
|
32
|
Zhang L, Liu H, Mu X, Cui J and Peng Z:
Dysregulation of Fra1 expression by Wnt/β-catenin signalling
promotes glioma aggressiveness through epithelial-mesenchymal
transition. Biosci Rep. 37:372017. View Article : Google Scholar
|
|
33
|
Li H, Yuan X, Yan D, Li D, Guan F, Dong Y,
Wang H, Liu X and Yang B: Long non-coding RNA MALAT1 decreases the
sensitivity of resistant glioblastoma cell lines to temozolomide.
Cell Physiol Biochem. 42:1192–1201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang J, Zhang JN, Chen WL, Wang GS, Mao Q,
Li SQ, Xiong WH, Lin YY, Ge JW, Li XX, et al: Effects of AQP5 gene
silencing on proliferation, migration and apoptosis of human glioma
cells through regulating EGFR/ERK/p38 MAPK signaling pathway.
Oncotarget. 8:38444–38455. 2017.PubMed/NCBI
|
|
35
|
Zhao L: Hirudin inhibits cell growth via
ERK/MAPK signaling in human glioma. Int J Clin Exp Med.
8:20983–20987. 2015.
|
